Abstract

The hyaluronan-mediated motility receptor (HMMR) is overexpressed in gastric cancer; however, the apparent role of HMMR has not been well defined owing to lack of detailed studies on gastric tumorigenesis. Therefore, we elucidated the functional and regulatory mechanisms of HMMR in gastric cancer. Using publicly available data, we confirmed HMMR overexpression in patients with gastric cancer. HMMR silencing decreased proliferation, migration, and invasion of gastric cancer cells, whereas HMMR overexpression reversed these effects. A gastric cancer xenograft mouse model showed statistically significant inhibition of tumor growth upon HMMR depletion. Previous data from cDNA microarray showed reduced HMMR expression upon inhibition of galectin-3. However, overexpression of galectin-3 increased HMMR expression, cell proliferation, and motility in gastric cancer cells, whereas HMMR silencing blocked these effects. Interestingly, galectin-3 interacted directly with C/EBPβ and bound to HMMR promoter to drive its transcription, and gastric cancer cell proliferation and motility. Altogether, high expression of HMMR promoted gastric cancer cell proliferation and motility and could be a prognostic factor in gastric cancer. In addition, HMMR expression was regulated by the interaction between C/EBPβ and galectin-3. Therefore, targeting HMMR along with galectin-3 and C/EBPβ complex could be a potential treatment strategy for inhibiting gastric cancer progression and metastasis. IMPLICATIONS: This study provides evidence that galectin-3 interacts with C/EBPβ in gastric cancer, and galectin-3 and C/EBPβ complex promotes gastric cancer cell progression and motility through upregulating HMMR expression.

Highlights

  • Gastric cancer is the fourth most common type of cancer and the second leading cause of cancer-related deaths worldwide [1, 2]

  • hyaluronan-mediated motility receptor (HMMR) expression was high in a majority of patients with gastric cancer, which correlated with their poor survival

  • HMMR expression levels were determined from gastric cancer patient data, available in the Gene Expression Omnibus (GEO) database (Fig. 1A–C)

Read more

Summary

Introduction

Gastric cancer is the fourth most common type of cancer and the second leading cause of cancer-related deaths worldwide [1, 2]. Despite current developments in diagnosis, as well as surgical and pharmacologic approaches, metastasized gastric cancer leads to poor prognosis and mortality [3,4,5,6,7]. Patients who present with the most favorable characteristics and undergo curative surgical resection often die of recurrent disease due to metastasis [8]. Several recent studies have focused on gastric cancer metastasis [9, 10], the underlying molecular mechanism of this phenomenon has not been completely elucidated [10]. We aimed to understand the underlying processes involved in gastric cancer metastasis, focusing on specific targets to improve gastric cancer prognosis.

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.